Aaron is a scientific and business development executive with a strong technical acumen, solid marketing fundamentals and a diverse sales background. His academic focus was in catalysis and small molecule development, upon receiving his PhD from Notre Dame he continued a Post Doctoral Fellowship track at The University of Pennylvania in organic chemistry. His career in (Bio)Pharmaceutical Drug Discovery & Development includes corporate experience in managerial positions at Sigma Aldrich, PPD Inc., AMRI Inc and Solvias AG.
He serves as a Scientific Advisor and consultant to several US based Biotechnology companies including Vindico Pharmaceuticals, Inc. & Transposagen.
Aaron's background includes all aspects of CRO/CMO contracted research, Bioanalysis, Cell-based assays and Preclinical to Phase I-III Trials requirements. He has extensive technology evaluation experience, as well as a superior understanding of the pharmaceutical advancement process from discovery/lead optimization through early development stages - including most critically late-stage clinical trials into commercial drug substances.
Notably, he has attained a wide array of expertise ranging from upstream intermediate API production to GMP manufacturing of both small-molecule therapeutics and biologics; to downstream analysis of drug product through to maximizing CRO partnerships.
He is a holder of multiple publications in top ranked journals, for instance The Journal of The American Chemical Society (JACS); as well as an awarded process patent covering the asymmetric catalytic formation of 3-continguous stereocenters within a a diversity oriented one-pot synthetic step as a complement to the 1990 Nobel Prize in Chemistry oxidation work from the labs of Dr. Barry Sharpless at Scripps Research Institute.
His academic specialty was focused on new methodologies in the field of zinc-mediated catalysis: Collaborated with medical physicians in the interdisciplinary R&D building at UPENN by synthesizing novel small-molecule therapeutics, which were used in drug-targeted in vivo fluorescent nano-delivery combination therapeutics in oncology for the pharmaceutical industry.